{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,9,28]],"date-time":"2025-09-28T15:35:44Z","timestamp":1759073744445},"reference-count":32,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2004,4,9]],"date-time":"2004-04-09T00:00:00Z","timestamp":1081468800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Psychopharmacology"],"published-print":{"date-parts":[[2004,10]]},"DOI":"10.1007\/s00213-004-1866-y","type":"journal-article","created":{"date-parts":[[2004,4,8]],"date-time":"2004-04-08T13:49:05Z","timestamp":1081432145000},"page":"94-100","source":"Crossref","is-referenced-by-count":20,"title":["Combined treatment of quetiapine with haloperidol in animal models of antipsychotic effect and extrapyramidal side effects: comparison with risperidone and chlorpromazine"],"prefix":"10.1007","volume":"176","author":[{"given":"Miho","family":"Tada","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kiyoharu","family":"Shirakawa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nobuya","family":"Matsuoka","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Seitaro","family":"Mutoh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2004,4,9]]},"reference":[{"key":"CR1","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1016\/S0924-977X(03)00004-X","volume":"13","author":"Ahlqvist","year":"2003","unstructured":"Ahlqvist J, Isacson R, Wahlestedt C, Salmi P (2003) Anti-cataleptic effects of clozapine, but not olanzapine and quetiapine, on SCH 23390- or raclopride-induced catalepsy in rats. Eur Neuropsychopharmacol 13:177?182","journal-title":"Eur Neuropsychopharmacol"},{"key":"CR2","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1016\/S0006-3223(97)00190-X","volume":"42","author":"Arvanitis","year":"1997","unstructured":"Arvanitis LA, Miller BG, The Seroquel Trial 13 Study Group (1997) Multiple fixed doses of ?Seroquel? (quetiapine) in patients with acute exacerbation of schizophrenia: a comparison with haloperidol and placebo. Biol Psychiatry 42:233?246","journal-title":"Biol Psychiatry"},{"key":"CR3","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1177\/026988110101500108","volume":"15","author":"Bantick","year":"2001","unstructured":"Bantick RA, Deakin JF, Grasby PM (2001) The 5-HT1A receptor in schizophrenia: a promising target for novel atypical neuroleptics? J Psychopharmacol 15:37?46","journal-title":"J Psychopharmacol"},{"key":"CR4","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1016\/S0197-0186(96)00124-6","volume":"30","author":"Burnet","year":"1997","unstructured":"Burnet PW, Eastwood SL, Harrisson PJ (1997) [3H]WAY-100635 for 5-HT1A receptor autoradiography in human brain: a comparison with [3H]8-OH-DPAT and demonstration of increased binding in the frontal cortex in schizophrenia. Neurochem Int 30:565?574","journal-title":"Neurochem Int"},{"key":"CR5","doi-asserted-by":"crossref","first-page":"S47","DOI":"10.1007\/BF00442559","volume":"99","author":"Casey","year":"1989","unstructured":"Casey DE (1989) Clozapine: neuroleptic-induced EPS and tardive dyskinesia. Psychopharmacology 99:S47?S53","journal-title":"Psychopharmacology"},{"key":"CR6","doi-asserted-by":"crossref","first-page":"S61","DOI":"10.1016\/S0920-9964(98)00160-1","volume":"35","author":"Casey","year":"1999","unstructured":"Casey DE (1999) Tardive dyskinesia and atypical antipsychotic drugs. Schizophr Res 35:S61?S66","journal-title":"Schizophr Res"},{"key":"CR7","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1017\/S0033291799001476","volume":"30","author":"Copolov","year":"2000","unstructured":"Copolov DL, Link CGG, Kowalcyk B (2000) A multicentre, double-blind, randomized comparison of quetiapine (ICI 204,636, ?Seroquel?) and haloperidol in schizophrenia. Psychol Med 30:95?105","journal-title":"Psychol Med"},{"key":"CR8","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1016\/S0149-2918(02)85018-4","volume":"24","author":"Cutler","year":"2002","unstructured":"Cutler AJ, Goldstein JM, Tumas JA (2002) Dosing and switching strategies for quetiapine fumarate. Clin Ther 24:209?222","journal-title":"Clin Ther"},{"key":"CR22","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1080\/13651500310001095","volume":"7","author":"De Nayer","year":"2003","unstructured":"De Nayer A, Windhager E, Irmansyam, Larmo I, Linderbauer B, Rittmannsberger H, Platz T, Jones AM, Whiteford JL, Altman CA, On behalf of the SPECTRUM study group (2003) Efficacy and tolerability of quetiapine in patients with schizophrenia switched from other antipsychotics. Int J Psychiatr Clin Pract 7:59?66","journal-title":"Int J Psychiatry Clin Pract"},{"key":"CR9","doi-asserted-by":"crossref","first-page":"975","DOI":"10.1016\/0306-4522(77)90120-8","volume":"2","author":"Fibiger","year":"1977","unstructured":"Fibiger HC, Miller JJ (1977) An anatomical and electrophysiological investigation of the serotonergic projection from the dorsal raphe nucleus to the substantia nigra in the rat. Neuroscience 2:975?987","journal-title":"Neuroscience"},{"key":"CR10","first-page":"205","volume":"21","author":"Guan","year":"2000","unstructured":"Guan HJ, Dai J, Zhu XZ (2000) Atypical antipsychotic effects of quetiapine fumarate in animal models. Acta Pharmacol Sin 21:205?210","journal-title":"Acta Pharmacol Sin"},{"key":"CR11","first-page":"107","volume":"32","author":"Hamner","year":"1996","unstructured":"Hamner MB, Arvanitis LA, Miller BG, Link CGG, Hong WW (1996) Plasma prolactin in schizophrenia subjects treated with Seroquel (ICI204,636). Psychopharmacol Bull 32:107?110","journal-title":"Psychopharmacol Bull"},{"key":"CR12","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1016\/S0006-8993(02)03570-9","volume":"956","author":"Ichikawa","year":"2002","unstructured":"Ichikawa J, Li Z, Dai J, Meltzer HY (2002) Atypical antipsychotic drugs, quetiapine, iloperidone, and melperone, preferentially increase dopamine and acetylcholine release in rat medial prefrontal cortex: role of 5-HT1A receptor agonism. Brain Res 956:349?357","journal-title":"Brain Res"},{"key":"CR13","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1016\/S0022-3956(98)00023-5","volume":"32","author":"Jibson","year":"1998","unstructured":"Jibson MD, Tandon R (1998) New atypical antipsychotic medications. J Psychiatr Res 32:215?228","journal-title":"J Psychiatr Res"},{"key":"CR14","doi-asserted-by":"crossref","first-page":"466","DOI":"10.1176\/ajp.153.4.466","volume":"153","author":"Kapur","year":"1996","unstructured":"Kapur S, Remington G (1996) Serotonin-dopamine interaction and its relevance to schizophrenia. Am J Psychiatry 153:466?476","journal-title":"Am J Psychiatry"},{"key":"CR15","doi-asserted-by":"crossref","first-page":"833","DOI":"10.4088\/JCP.v61n1105","volume":"61","author":"Kinon","year":"2000","unstructured":"Kinon BJ, Basson BR, Gilmore JA, Malcolm S, Stauffer VL (2000) Strategies for switching from conventional antipsychotic drugs or risperidone to olanzapine. J Clin Psychiatry 61:833?840","journal-title":"J Clin Psychiatry"},{"key":"CR16","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/0006-8993(80)90250-4","volume":"186","author":"Kooy","year":"1980","unstructured":"Kooy DV, Hattori T (1980) Dorsal raphe cells with collateral projections to the caudate-putamen and substantia nigra: a fluorescent retrograde double labeling study in the rat. Brain Res 186:1?7","journal-title":"Brain Res"},{"key":"CR17","doi-asserted-by":"crossref","first-page":"231","DOI":"10.3109\/13651509709024734","volume":"1","author":"Meats","year":"1997","unstructured":"Meats P (1997) Quetiapine (?Seroquel?); an effective and well-tolerated atypical antipsychotic. Int J Psychiatr Clin Pract 1:231?239","journal-title":"Int J Psychiatry Clin Pract"},{"key":"CR18","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1192\/S0007125000296876","volume":"160","author":"Meltzer","year":"1992","unstructured":"Meltzer HY (1992) The importance of serotonin-dopamine interactions in the action of clozapine. Br J Psychiatry 160:22?29","journal-title":"Br J Psychiatry"},{"key":"CR19","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1016\/0024-3205(75)90482-8","volume":"17","author":"Meltzer","year":"1975","unstructured":"Meltzer HY, Daniels S, Fang VS (1975) Clozapine increases rat serum prolactin levels. Life Sci 17:339?342","journal-title":"Life Sci"},{"key":"CR20","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1007\/BF02244925","volume":"112","author":"Migler","year":"1993","unstructured":"Migler BM, Warawa EJ, Malick JB (1993) Seroquel: behavioral effects in conventional and novel tests for atypical antipsychotic drug. Psychopharmacology 112:299?307","journal-title":"Psychopharmacology"},{"key":"CR21","first-page":"853","volume":"295","author":"Millan","year":"2000","unstructured":"Millan MJ (2000) Improving the treatment of schizophrenia: focus on serotonin (5-HT)1A receptors. J Pharmacol Exp Ther 295:853?861","journal-title":"J Pharmacol Exp Ther"},{"key":"CR23","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1038\/333174a0","volume":"333","author":"Nedergaard","year":"1988","unstructured":"Nedergaard S, Bolam JP, Greenfield SA (1988) Facilitation of a dendritic calcium conductance by 5-hydroxytryptamine in the substantia nigra. Nature 333:174?177","journal-title":"Nature"},{"key":"CR24","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1016\/S0014-2999(98)00483-X","volume":"355","author":"Newman-Tancredi","year":"1998","unstructured":"Newman-Tancredi A, Gavaudan S, Conte C, Chaput C, Touzard M, Verriele L, Audinot V, Millan MJ (1998) Agonist and antagonist actions of antipsychotic agents at 5-HT1A receptors: a [35S]GTP?S binding study. Eur J Pharmacol 355:245?256","journal-title":"Eur J Pharmacol"},{"key":"CR25","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1016\/0006-8993(77)90302-X","volume":"122","author":"Olpe","year":"1977","unstructured":"Olpe HR, Koella WP (1977) The response of striatal cells upon stimulation of the dorsal and median raphe nuclei. Brain Res 122:357?360","journal-title":"Brain Res"},{"key":"CR26","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1111\/j.1600-0447.1997.tb10162.x","volume":"96","author":"Peuskens","year":"1997","unstructured":"Peuskens J, Link CGG (1997) A comparison of quetiapine and chlorpromazine in the treatment of schizophrenia. Acta Psychiatr Scand 96:265?273","journal-title":"Acta Psychiatr Scand"},{"key":"CR27","first-page":"137","volume":"26","author":"Purdon","year":"2001","unstructured":"Purdon SE, Malla A, Labelle A, Lit W (2001) Neuropsychological change in patients with schizophrenia after treatment with quetiapine or haloperidol. J Psychiatry Neurosci 26:137?149","journal-title":"J Psychiatry Neurosci"},{"key":"CR28","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/S0024-3205(00)00911-5","volume":"68","author":"Richelson","year":"2000","unstructured":"Richelson E, Souder T (2000) Binding of antipsychotic drugs to human brain receptors. Focus on newer generation compounds. Life Sci 68:29?39","journal-title":"Life Sci"},{"key":"CR29","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1007\/BF02244923","volume":"112","author":"Saller","year":"1993","unstructured":"Saller CF, Salama AI (1993) Seroquel: biochemical profile of a potential atypical antipsychotic. Psychopharmacology 112:285?292","journal-title":"Psychopharmacology"},{"key":"CR30","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1016\/S0920-9964(01)00268-7","volume":"53","author":"Velligan","year":"2002","unstructured":"Velligan DI, Newcomer J, Pultz J, Csernansky J, Hoff AL, Mahurin R, Miller AL (2002) Does cognitive function improve with quetiapine in comparison to haloperidol? Schizophr Res 53:239?248","journal-title":"Schizophr Res"},{"key":"CR31","first-page":"63","volume":"58","author":"Weiden","year":"1997","unstructured":"Weiden PJ, Aquila R, Dalheim L, Standard JM (1997) Switching antipsychotic medications. J Clin Psychiatry 58:63?72","journal-title":"J Clin Psychiatry"},{"key":"CR32","unstructured":"Weiss JM, Kilts CD (1995) Animal models of depression and schizophrenia. In: Schatzberg AF, Nemeroff CB (eds) Textbook of psychopharmacology. American Psychiatric Association, USA, pp 81?123"}],"container-title":["Psychopharmacology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00213-004-1866-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00213-004-1866-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00213-004-1866-y","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,3,31]],"date-time":"2020-03-31T22:42:23Z","timestamp":1585694543000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00213-004-1866-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2004,4,9]]},"references-count":32,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2004,10]]}},"alternative-id":["1866"],"URL":"https:\/\/doi.org\/10.1007\/s00213-004-1866-y","relation":{},"ISSN":["0033-3158","1432-2072"],"issn-type":[{"value":"0033-3158","type":"print"},{"value":"1432-2072","type":"electronic"}],"subject":[],"published":{"date-parts":[[2004,4,9]]}}}